Literature DB >> 7559077

Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer.

A Komiya1, H Suzuki, S Aida, R Yatani, J Shimazaki.   

Abstract

To study mutation of the CDKN2 gene in prostate cancer, samples from 51 Japanese patients and four human prostate cancer cell lines were examined by single-strand conformation polymorphism analysis and direct sequencing. Only one out of 51 (2%) patients revealed a mutation, which was a 24 bp deletion from the 5'-untranslated region to codon 3, resulting in loss of the initiation site. One of the four cell lines revealed a missense mutation, a GAC-->TAC (Asp-->Tyr) at codon 84. These results indicate that mutation of the CDKN2 gene is rare in prostate cancer and thus does not contribute significantly to the pathogenesis of human prostate cancer. Prostate cancer cell lines may acquire more frequent abnormality of the CDKN2 gene than tumor tissues.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7559077      PMCID: PMC5920883          DOI: 10.1111/j.1349-7006.1995.tb02443.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


cyclin‐dependant kinase 4 inhibitor multiple tumor suppressor 1 polymerase chain reaction single‐strand conformation polymorphism
  26 in total

1.  Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice.

Authors:  D D Mickey; K R Stone; H Wunderli; G H Mickey; R T Vollmer; D F Paulson
Journal:  Cancer Res       Date:  1977-11       Impact factor: 12.701

2.  Allelotyping of human prostatic adenocarcinoma.

Authors:  K Kunimi; U S Bergerheim; I L Larsson; P Ekman; V P Collins
Journal:  Genomics       Date:  1991-11       Impact factor: 5.736

3.  Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas.

Authors:  D G Walker; W Duan; E A Popovic; A H Kaye; F H Tomlinson; M Lavin
Journal:  Cancer Res       Date:  1995-01-01       Impact factor: 12.701

4.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.

Authors:  T Nobori; K Miura; D J Wu; A Lois; K Takabayashi; D A Carson
Journal:  Nature       Date:  1994-04-21       Impact factor: 49.962

5.  Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas.

Authors:  L Xu; D Sgroi; C J Sterner; R L Beauchamp; D M Pinney; S Keel; K Ueki; J L Rutter; A J Buckler; D N Louis
Journal:  Cancer Res       Date:  1994-10-15       Impact factor: 12.701

6.  Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma.

Authors:  T Mori; K Miura; T Aoki; T Nishihira; S Mori; Y Nakamura
Journal:  Cancer Res       Date:  1994-07-01       Impact factor: 12.701

7.  CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.

Authors:  E E Schmidt; K Ichimura; G Reifenberger; V P Collins
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701

8.  Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4l (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas.

Authors:  N Hayashi; Y Sugimoto; E Tsuchiya; M Ogawa; Y Nakamura
Journal:  Biochem Biophys Res Commun       Date:  1994-08-15       Impact factor: 3.575

9.  Infrequent somatic mutation of the MTS1 gene in primary bladder carcinomas.

Authors:  M Kai; H Arakawa; Y Sugimoto; Y Murata; M Ogawa; Y Nakamura
Journal:  Jpn J Cancer Res       Date:  1995-03

10.  State of adenomatous polyposis coli gene and ras oncogenes in Japanese prostate cancer.

Authors:  H Suzuki; S Aida; S Akimoto; T Igarashi; R Yatani; J Shimazaki
Journal:  Jpn J Cancer Res       Date:  1994-08
View more
  8 in total

1.  CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A.

Authors:  P Schraml; K Struckmann; R Bednar; W Fu; T Gasser; K Wilber; J Kononen; G Sauter; M J Mihatsch; H Moch
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

2.  Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma.

Authors:  A K El-Naggar; S Lai; G Clayman; J K Lee; M A Luna; H Goepfert; J G Batsakis
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

Review 3.  The AR dependent cell cycle: mechanisms and cancer relevance.

Authors:  Matthew J Schiewer; Michael A Augello; Karen E Knudsen
Journal:  Mol Cell Endocrinol       Date:  2011-07-12       Impact factor: 4.102

Review 4.  Molecular biology of prostate cancer.

Authors:  X B Shi; P H Gumerlock; R W deVere White
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 5.  The role of the cell cycle in genitourinary carcinoma.

Authors:  T W McGarvey; S B Malkowicz
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

6.  Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer.

Authors:  Wennuan Liu; Chunmei Carol Xie; Yi Zhu; Tao Li; Jishan Sun; Yu Cheng; Charles M Ewing; Sue Dalrymple; Aubrey R Turner; Jielin Sun; John T Isaacs; Bao-Li Chang; Siqun Lilly Zheng; William B Isaacs; Jianfeng Xu
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

7.  PRLTS gene alterations in human prostate cancer.

Authors:  A Komiya; H Suzuki; T Ueda; S Aida; N Ito; T Shiraishi; R Yatani; M Emi; K Yasuda; J Shimazaki; H Ito
Journal:  Jpn J Cancer Res       Date:  1997-04

8.  Microsatellite instability and other molecular abnormalities in human prostate cancer.

Authors:  H Suzuki; A Komiya; S Aida; S Akimoto; T Shiraishi; R Yatani; T Igarashi; J Shimazaki
Journal:  Jpn J Cancer Res       Date:  1995-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.